Fred Hutch Cancer Center scientists have developed an experimental strategy to give genetically engineered CAR T cells help they'd normally find within lymph nodes — but on the go, within the tumor.

UCLA scientists have developed a next-generation CAR-T cell therapy that can overcome the immunosuppressive tumor microenvironment, a protective shield that tumors use to weaken immune cells, block ...

A new editorial perspective was published in Volume 17 of Oncotarget on February 20, 2026, titled "CAR-T therapy: Trailblazing CAR(ing) in cancer treatment." ...

Chimeric antigen receptor T cell (CAR-T) therapies have revolutionized treatment for various blood cancers. When traditional treatments fail, CAR-T therapies provide a second highly effective option.

A new CAR T therapy design uses the approved drug venetoclax to temporarily disengage engineered immune cells from tumors. The reversible “off-switch” enhances safety and preserves cell function.

UCLA scientists have developed a next-generation CAR-T cell therapy that can overcome the immunosuppressive tumor microenvironment, a protective shield that tumors use to weaken immune cells, block ...

Researchers at the University of Chicago have developed a modular cancer immunotherapy that can be switched on, off or reprogramed to attack different cancers. Promising initial testing results, ...

After nearly a decade of treatment, a Texas woman reached remission through an FDA-approved cellular therapy for chronic lymphocytic leukemia.